04:22 PM EST, 03/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) reported a Q4 net loss late Thursday of $0.32 per diluted share, compared with net income of $4.33 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.86.

Revenue for the quarter ended Dec. 31 was $34 million, down from $160.3 million a year earlier.

Analysts surveyed by Capital IQ expected $37.9 million.

Cash, cash equivalents, and restricted cash were at $348.9 million as of Dec. 31, the company said, adding the cash runway was extended to Q1 2027.